Afuco™ Anti-Human KLKB1 ADCC Recombinant Antibody (DX-2930), ADCC Enhanced (CAT#: AFC-452CL)

Figure 1 is a schematic illustration of a microplate-based pKal activity assay, with accompanying experiment showing the inhibitory activity of DX-2930 on pKal activity in treated monkeys.

Figure 2 shows experiments in plasma from placebo/vehicle treated monkeys as well as a DX-2930 control spiked into this same plasma.

Figure 3 shows the inhibitory activity of DX-2930 on pKal activation in cynomolgus monkeys.

Multi-Dose DX-2930 was used in Cynomolgus Monkeys Kininogen Western Blot Analysis of Day 4 APTT Plasma Samples (With or Without Plasma Activation by Kaolin or 15 pg/mL Dextran Sulfate)

Figure 4 illustrates an exemplary HMWK Ex Vivo activation assay for examining the inhibitory activity of an example pKal inhibitor Dx-2930, using both Protein Simple Western analysis and traditional Western blot analysis.

The HMWK Ex Vivo Activation Assay described herein showed that minimal Levels of DX-2930 inhibited pKal activation, which outperformed endogenous CI inhibitor alone in normal human plasma.

Figure 5 depicts an HMWK Ex Vivo activation assay showing Protein Simple raw data for Factor Xlla activated plasma with DX2930 titration.